WarfarinPharmacogeneticsAnticoagulantsVitamin K Epoxide ReductasesMixed Function OxygenasesAryl Hydrocarbon HydroxylasesAcenocoumarolbeta-AlanineInternational Normalized RatioProthrombin TimeHemorrhageThromboembolismAdministration, OralVitamin KPhenindioneAtrial FibrillationPhenprocoumonIndividualized MedicineThiophenesPyridonesThrombophlebitisBlood CoagulationBenzimidazolesAntithrombinsDrug MonitoringVenous ThromboembolismBlood Coagulation TestsInternational CooperationCytochrome P-450 CYP2D6Polymorphism, GeneticHeparin, Low-Molecular-WeightRodenticidesFactor XaThrombosisVenous ThrombosisProthrombinPartial Thromboplastin TimeAspirinGenotypePlatelet Aggregation InhibitorsHeparinTreatment OutcomeStrokeDrug InteractionsLupus Coagulation InhibitorBiomarkers, PharmacologicalPulmonary EmbolismBlood Coagulation FactorsMicrobial ConsortiaProtein CMorpholines4-HydroxycoumarinsFibrinolytic AgentsPolymorphism, Single NucleotideDose-Response Relationship, DrugEmbolismRisk FactorsDrug-Related Side Effects and Adverse ReactionsBlood Coagulation DisordersDrug Dosage CalculationsCoumarinsIntracranial HemorrhagesClinical Trials as TopicInternational AgenciesPharmaceutical PreparationsThrombophiliaGenetic VariationDrug TherapyEnoxaparinRandomized Controlled Trials as TopicHematomaFactor XOral Surgical ProceduresDicumarolHeart Valve ProsthesisGenetic TestingTime FactorsCytochrome P-450 Enzyme SystemRisk AssessmentCoagulantsMetabolic Detoxication, DrugProspective StudiesCerebral HemorrhagePostoperative HemorrhageThromboplastinThrombinAzetidinesPharmacy ResidenciesPyrazolesRecurrenceFactor VIIFollow-Up StudiesPerioperative CareRetrospective StudiesThrombin TimeVitamin K 1Dihydrouracil Dehydrogenase (NADP)Drug Therapy, CombinationFibrin Fibrinogen Degradation ProductsProtein S